CVS Health (CVS) Reshapes Its Board, Is It Still A Bargain?

CVS Health (CVS) is in focus after announcing board changes, with longtime director Larry M. Robbins resigning and JPMorgan executive Teresa Heitsenrether scheduled to join the board later in 2026.

Shares of CVS Health have pulled back over the past month, with a 30 day share price return of 11.91% down, even though the year to date share price return is 17.71%. Over longer periods, total shareholder returns of 35.29% over one year and 58.26% over three years suggest that investors who stayed invested through recent news, including board changes and community focused initiatives such as the Home Team Heroes contest, have been rewarded while shorter term momentum has cooled.

Scan how CVS Health compares with a curated group of resilient healthcare stocks by reviewing the 75 resilient stocks with low risk scores that have kept risk scores in check while the market mood has shifted.

After a strong year to date move followed by a sharp 30 day pullback, CVS Health now sits at a crossroads between recent optimism and cooling momentum. Has most of the upside already played out, or does the valuation still leave room ahead?

Most Popular Narrative: 18% Undervalued

With CVS Health last closing at $94.32 against a narrative fair value of $114.88, the current pullback sits against a valuation framework that assumes meaningful earnings compounding supported by its integrated healthcare model.

Integration of recent and ongoing acquisitions (such as Aetna, Oak Street, and Signify Health) and vertical alignment between insurance, pharmacy, and care delivery provide substantial cross-selling and synergy opportunities, supporting long-term operating margin and earnings growth as margin recovery initiatives gain traction.

Read the complete narrative.

Want to see what earnings path needs to materialize for that fair value on CVS Health? The narrative leans on steady revenue expansion, firmer margins, and a future profit multiple that assumes the market rewards that progress. Curious which precise growth and profitability assumptions sit underneath those expectations and how sensitive the outcome is to each input? Read on to test whether those building blocks line up with your own view.

Result: Fair Value of $114.88 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, CVS Health still faces pressure from medical cost trends and reimbursement, and setbacks in these areas could challenge the earnings, margin and valuation narrative that investors are watching.

Find out about the key risks to this CVS Health narrative.

Next Steps

With sentiment on CVS Health split between concern and optimism, it helps to check the underlying data yourself and move quickly to shape your own view using the 4 key rewards and 2 important warning signs.

Looking for more investment ideas beyond CVS Health?

If you are serious about building a stronger portfolio, do not stop with CVS Health. Use the Simply Wall Street Screener to uncover other opportunities that could fit your goals.

• Target potential upside by scanning a 51 high quality undervalued stocks that combine solid fundamentals with prices that may not fully reflect their underlying businesses.
• Strengthen your income stream by reviewing 11 dividend fortresses that focus on companies offering higher yields with an emphasis on resilience.
• Protect your capital by shortlisting a list of solid balance sheet and fundamentals (51 results) that prioritises financial strength and durable business models.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com